These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2737132)

  • 1. [The pharmacokinetics of the antitumor preparation of dimetinur].
    Ostrovskaia LA; Rykova VA; Konradov AA; Ivanov AS; Korman DB
    Eksp Onkol; 1989; 11(2):57-62. PubMed ID: 2737132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [14Co-dimetinur distribution in mice in relation to the stage of the development of tumor process].
    Ostrovskaia LA; Rykova VA; Kondarov AA; Etvesh L; Shimon-Trompler E; Sokolova IS; Korman DB
    Eksp Onkol; 1990; 12(1):70-4. PubMed ID: 2298149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamics of the chromosomal damages to Ehrlich ascitic cancer and bone marrow cells of mice by the antitumor preparation dimetinur].
    Fomina MM; Bogoslovskaia EP; Konradov AA; Ostrovskaia LA
    Eksp Onkol; 1986; 8(3):70-4. PubMed ID: 3720644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative evaluation of the antitumor, cytogenetic and immunodepressive effects of dimetinur when used perorally and parenterally].
    Osatrovskaia LA; Fomina MM; Bogoslovskaia EP; Potapov SL; Korman DB
    Eksp Onkol; 1988; 10(6):44-8. PubMed ID: 3243195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
    Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological disposition of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in mice.
    Rahman A; Luc PV; Schein PS; Woolley PV
    Cancer Res; 1984 Jan; 44(1):149-53. PubMed ID: 6690033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
    Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The dose-dependent cytogenetic and growth-inhibiting effects of a new antitumor preparation from the nitrosourea group].
    Fomina MM; Dzhamanbaev ZhA; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1991; (3):436-44. PubMed ID: 1955617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
    Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic studies of anticancer drugs in tumor-bearing animals.
    Donelli MG; D'Incalci M; Garattini S
    Cancer Treat Rep; 1984 Feb; 68(2):381-400. PubMed ID: 6697328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.